Pharmaceuticals

Drug Development Biotechnology Drug Pricing Acquisitions Manufacturing Drug Manufacturing Vaccine Development Market Competition Mergers and Acquisitions Market Trends

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

The buyout expands UCB's push into T‑cell engager drugs for autoimmune diseases.

Vertex Posts Mixed Quarter as Profit Beats, Sales Miss and Outlook Holds

Purdue Pharma Shuts Down as $7.4 Billion Opioid Settlement Takes Effect

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Hims & Hers Expands Access to Lilly Weight-Loss Drugs as Shares Jump 7%

West Pharmaceutical Raises 2026 Guidance After Double-Digit Q1 Growth

Amneal to Acquire Kashiv BioSciences to Expand in Biosimilars

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Boehringer Ingelheim to Invest £150 Million in London AI Drug Discovery Centre

Definium Therapeutics Jumps to 52-Week High After Trump Order on Psychedelic Treatments

Roche Starts Placebo-Controlled Phase 3 Trial of Elevidys to Pursue EU Approval

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety